PDCD1 and colorectal carcinoma: For example, the metastatic microsatellite stable (MSS) CRC patients are not good responders to the anti-PD-1 immunotherapy such as Pembrolizumab, but in the phase 1 clinical trial (NCT02671435) combining the Monalizumab (anti-NKG2A antibody) and Durvalumab (anti-PD-L1 antibody), three out of 39 patients were evaluated as partial response (PR) and 19 patients as stable disease (SD).